

## Serum levels of alpha-1 microglobulin in recipients of renal allografts

Lars Bäckman<sup>1</sup>, Olle Ringdén<sup>1,2</sup>, and Francesco Dati<sup>3</sup>

<sup>1</sup> Department of Transplantation Surgery B56 and <sup>2</sup> Department of Clinical Immunology, Karolinska Institute, Huddinge Hospital, S-141 86 Huddinge, Sweden

<sup>3</sup> Research Laboratories of Behringwerke AG, D-3550 Marburg, Federal Republic of Germany

**Abstract.** Serum levels of  $\alpha_1$  microglobulin ( $s\text{-}\alpha_1\text{m}$ ) in 92 recipients of renal transplants were elevated during pretransplant uremia ( $P < 0.001$ ), acute rejection ( $P < 0.01$ ), and cyclosporin-induced nephrotoxicity ( $P < 0.01$ ). In patients with stable renal function, those treated with cyclosporin had higher  $s\text{-}\alpha_1\text{m}$  than those receiving azathioprine:  $81 \pm 4$  and  $64 \pm 3$  mg/l (mean  $\pm$  SEM), respectively ( $P < 0.05$ ). The serum creatinine levels were  $127 \pm 5$  and  $115 \pm 7$   $\mu\text{mol/l}$  (mean  $\pm$  SEM), respectively (N.S.). Two of the patients with normal serum creatinine had normal  $s\text{-}\alpha_1\text{m}$  levels. There were positive linear correlations between  $s\text{-}\alpha_1\text{m}$  and serum creatinine levels during stable renal function, rejection, cyclosporin-induced nephrotoxicity, and cytomegalovirus infections ( $r = 0.7\text{--}0.8$ ,  $P < 0.01\text{--}0.001$ ) and between  $s\text{-}\alpha_1\text{m}$  and  $\beta_2$  microglobulin ( $\beta_2\text{m}$ ) during the same conditions ( $r = 0.5\text{--}0.8$ ,  $P < 0.01\text{--}0.001$ ). During infections, serum creatinine and  $\beta_2\text{m}$  increased ( $P < 0.001$ ), but  $s\text{-}\alpha_1\text{m}$  did not.  $s\text{-}\alpha_1\text{m}$  values did not distinguish between rejection and cyclosporin-induced nephrotoxicity. It is concluded that  $s\text{-}\alpha_1\text{m}$  might be a valuable complement to serum creatinine levels in the evaluation of renal function in renal transplant recipients.

**Key words:**  $\alpha_1$  Microglobulin -  $\beta_2$  Microglobulin - Renal transplantation - Cyclosporin nephrotoxicity - Acute rejection - Infections.

Alpha-1 microglobulin ( $\alpha_1\text{m}$ ) is a low molecular weight glycoprotein (mol.wt.33,000) containing 167 amino acid residues which is present in serum and other body fluids [5]. The exact function and site of its production are presently unknown, but the liver has been proposed as being the main site of synthesis [8]. It has been suggested that  $\alpha_1\text{m}$  is filtered freely by the glomeruli and then reabsorbed and

catabolized by the proximal tubular epithelium in the same manner as other low molecular weight proteins, such as  $\beta_2$  microglobulin ( $\beta_2\text{m}$ ) [15, 17]. Serum levels of low molecular weight proteins have been proposed as being more reliable indicators of renal function than serum creatinine ( $s\text{-crea}$ ). Several reports have demonstrated a positive linear correlation between serum  $\alpha_1\text{m}$  ( $s\text{-}\alpha_1\text{m}$ ) and  $s\text{-crea}$  and creatinine clearance [7, 10, 17, 18]. Normal values have ranged from 20 to 42 mg/l using single radial immunodiffusion [18].

Increased  $s\text{-}\alpha_1\text{m}$  levels have been observed during impaired renal function, and disturbances in tubular reabsorption have led to increased  $\alpha_1\text{m}$  levels in urine [17]. In addition, elevated  $s\text{-}\alpha_1\text{m}$  levels have been reported in connection with plasma cell dyscrasias, leukemias, solid tumors, and hepatitis [16].

The purpose of the present study was to monitor the serum levels of  $\alpha_1\text{m}$  during different states of renal deterioration in renal transplant recipients. Consideration was also given to whether  $s\text{-}\alpha_1\text{m}$  levels could be used to differentiate between rejection, cyclosporin (Cs)-induced nephrotoxicity, and infections [9].

### Patients and methods

Ninety-two recipients of renal allografts (35 females and 57 males) with a median age of 46 years (range 11-73) were studied under conditions of stable renal function, uremia, acute rejection, Cs-induced nephrotoxicity, cytomegalovirus (CMV) infections, and other infections. These patients had received renal grafts from 80 cadaveric and 12 living-related donors. Azathioprine (Aza), in combination with prednisolone, was used for immunosuppressive treatment of 33 patients, while Cs, in combination with prednisolone, was used for 59 patients [14]. Forty-nine patients were studied during stable renal function. These individuals showed no signs of rejection, clinically significant Cs nephrotoxicity, or infection; they had an  $s\text{-crea} < 200$   $\mu\text{mol/l}$ . In the stable group, 21 patients received Aza in combination with prednisolone, while 28 received Cs in combination with prednisolone. The patients with uremia ( $n = 25$ ) were investigated immediately prior to transplantation and were all on dialysis.

### Diagnosis of rejection, Cs nephrotoxicity, and infection

Twenty-seven patients with deteriorated renal function were diagnosed as having an ongoing acute rejection. Twenty-five of these cases were diagnosed by means of biopsy; for the other two this diagnosis was made on the basis of their clinical, Aza-treated condition and the fact that there was improvement in renal function after antirejection therapy with intravenous methylprednisolone. Acute Cs-induced nephrotoxicity ( $n=18$ ) was diagnosed by means of biopsy in eight cases and by improvement in renal function after reduction of the Cs dose ( $n=10$ ). These patients had a mean plasma Cs level of  $475 \pm 77$  ng/ml ( $\pm$  SEM) prior to dose reduction and of  $175 \pm 32$  ng/ml ( $\pm$  SEM) when renal function improved.

Infections ( $n=30$ ) were diagnosed clinically, serologically, from a positive culture, or by isolation of the causative microorganism. The serology was positive in all 18 patients with CMV infections (positive IgM and/or a fivefold rise in IgG titer), and CMV was isolated from blood and/or urine in 15 of these patients. The other infections ( $n=12$ ) consisted of urosepticemia ( $n=3$ ), pyelonephritis ( $n=2$ ), bronchopneumonia ( $n=1$ ), septicemia ( $n=1$ ), *Pneumocystis carinii* pneumonia ( $n=1$ ), osteitis ( $n=1$ ), pancreatitis ( $n=1$ ), acute gastroenteritis ( $n=1$ ), and hepatitis B infection ( $n=1$ ).

**Table 1.** Serum levels of  $\alpha_1m$  and creatinine in patients with stable renal function and uremia. \*  $P<0.05$ ; \*\*  $P<0.001$

	<i>n</i>	Serum $\alpha_1$ microglobulin <sup>a</sup> (mean $\pm$ SEM)	Serum creatinine <sup>b</sup> (mean $\pm$ SEM)
Stable function	49	$74 \pm 3^{**}$	$121 \pm 4^{**}$
Cs-treated	28	$81 \pm 4^*$	$127 \pm 5$ N.S.
Aza-treated	21	$64 \pm 3^*$	$115 \pm 7$ N.S.
Uremia	25	$268 \pm 16^{**}$	$868 \pm 40^{**}$

<sup>a</sup> mg/l

<sup>b</sup>  $\mu$ mol/l

### Analyses of $\alpha_1m$ , $\beta_2m$ , creatinine, and cyclosporin

Serum samples were frozen at  $-20^\circ\text{C}$  and later analyzed.  $\alpha_1m$ -Levels were measured by single radial immunodiffusion, using reagents developed at Behringwerke AG (Marburg, FRG).  $\beta_2m$ -Levels were determined by a competitive enzyme-linked immunoassay with a normal range of 1.2-2.5 mg/l (Behringwerke AG, Marburg, FRG). S-crea (normal value  $<115$   $\mu$ mol/l) was analyzed using the kinetic Jaffé method [3]. The accuracy of this method has been evaluated using a reference method based on isotope dilution and mass spectrometry. Cs plasma trough levels were analyzed using a polyclonal radioimmunoassay (Sandoz, Basel, Switzerland) with a range of 50-2000 ng/ml.


### Statistics

The Mann-Whitney U ranking test was used for statistical comparisons. Values from the day of diagnosis during the different conditions were selected for comparisons. Fischer's exact test and linear correlation analysis were also used when appropriate.

### Results

S- $\alpha_1m$  and s-crea were significantly elevated during pretransplant uremia (Table 1). Levels were higher during uremia than during any of the other conditions investigated (stable function, rejection, Cs nephrotoxicity, CMV infections, and other infections;  $P<0.001$ , Fig. 1). The lowest s- $\alpha_1m$  and s-crea were obtained during stable function. Patients with stable function who were treated with Cs had significantly higher s- $\alpha_1m$  than patients treated with Aza ( $P<0.05$ ), while s-crea was not significantly higher (Table 1). Cs-treated patients with stable renal function had a mean plasma Cs concentration of  $160 \pm 28$  ng/ml ( $\pm$  SEM).

Twenty patients had normal s-crea levels



**Fig. 1.** Individual serum levels of  $\alpha_1m$  and creatinine during stable renal function, rejection (Rej), cyclosporin-induced nephrotoxicity (Cs tox), cytomegalovirus infection (CMV) and other infections. Horizontal lines indicate means, vertical bars indicate SEM




Fig. 2. Linear correlations between serum levels of  $\alpha_1m$  and creatinine during stable renal function, uremia, rejection, cyclosporin-induced nephrotoxicity, CMV, and other infections

Table 2. Linear correlation between serum levels of  $\alpha_1m$  and  $\beta_2m$  in patients with stable renal function, uremia, acute rejection, cyclosporin nephrotoxicity, CMV, and other infections. \*  $P < 0.01$ ; \*\*  $P < 0.001$

	<i>n</i>	Serum $\alpha_1$ microglobulin <sup>a</sup> (mean $\pm$ SEM)	Serum $\beta_2$ microglobulin <sup>a</sup> (mean $\pm$ SEM)	<i>R</i> -value
Stable function	49	74 $\pm$ 3	3.7 $\pm$ 0.2	0.6**
Uremia	25	268 $\pm$ 16	40.2 $\pm$ 4.4	0.5*
Acute rejection	27	107 $\pm$ 9	15.0 $\pm$ 2.5	0.8**
Cyclosporin nephrotoxicity	18	101 $\pm$ 9	10.2 $\pm$ 1.3	0.8**
CMV infections	18	90 $\pm$ 11	12.2 $\pm$ 2.7	0.7*
Other infections	12	91 $\pm$ 14	6.2 $\pm$ 0.9	0.1 N.S.

<sup>a</sup> mg/ml

(< 115  $\mu$ mol/l). Of these, only two had s- $\alpha_1m$  levels  $\leq$  42 mg/l. Both of these patients were treated with Aza. None of the 28 patients with stable function who were receiving Cs had s- $\alpha_1m$   $\leq$  42 mg/l.

### Rejection and nephrotoxicity

Both s- $\alpha_1m$  and s-crea were elevated during rejection in comparison to stable function ( $P < 0.01$  and  $P < 0.001$ , respectively, Fig. 1). Elevated levels of s- $\alpha_1m$  and s-crea were also found during Cs nephrotoxicity ( $P < 0.01$  and  $P < 0.001$ , respectively). There were no differences in s- $\alpha_1m$  or s-crea levels during rejection and Cs nephrotoxicity.

### Infections

S-crea was elevated during CMV and other infections in comparison to stable function ( $P < 0.01$  for both groups); s- $\alpha_1m$  was not, however. In 3 of the 30 patients with CMV and other infections, s- $\alpha_1m$  increased beyond the range of values for patients with stable function. For s-crea this was true in 17 of the 30 cases ( $P < 0.001$ , Fischer's exact test).

### Correlations between $\alpha_1m$ , creatinine, and $\beta_2m$ levels

The linear correlation (*r*) between s- $\alpha_1m$  and s-crea was 0.7 ( $P < 0.001$ ) during stable renal function, 0.3 (N.S.) during uremia, 0.8 ( $P < 0.001$ ) during rejection, 0.7 ( $P < 0.001$ ) during Cs nephrotoxicity, 0.8 ( $P < 0.001$ ) during CMV infections, and -0.1 (N.S.) during the other infections (Fig. 2). The linear correlations between s- $\alpha_1m$  and s- $\beta_2m$  during the different conditions investigated are given in Table 2. The correlations were positive and significant during all conditions except the other infections.

### Discussion

The highest s- $\alpha_1m$  levels were found during deterioration in renal function, i.e., uremia, rejection, and Cs nephrotoxicity. There were linear correlations between s- $\alpha_1m$ , s-crea, and s- $\beta_2m$ . The lowest values were observed in patients with stable renal function.

Slightly higher  $s\text{-}\alpha_1\text{m}$  was seen during infections, although this did not reach significance. Only 2 of the 20 patients with a normal  $s\text{-crea}$  also had normal  $s\text{-}\alpha_1\text{m}$  levels. Cs patients with stable function had higher  $s\text{-}\alpha_1\text{m}$  levels than Aza patients, whereas their  $s\text{-crea}$  did not differ (Table 1). Patients treated with Cs generally have a poorer renal function with a reduced glomerular filtration rate than patients treated with Aza [1, 4, 6].

These data suggest that  $s\text{-}\alpha_1\text{m}$  is a more sensitive indicator of renal function than  $s\text{-crea}$ . This is in line with previous reports of an increase in  $s\text{-}\alpha_1\text{m}$  preceding increases in  $s\text{-crea}$  and  $s\text{-}\beta_2\text{m}$  during a mild degree of renal dysfunction [7, 17]. The poor correlation between  $s\text{-}\alpha_1\text{m}$  and  $s\text{-crea}$  during uremia may have been influenced by the dialysis treatment, which eliminated  $\alpha_1\text{m}$  and  $\text{crea}$  by different forms of kinetics. However, the correlation between  $s\text{-}\alpha_1\text{m}$  and  $s\text{-}\beta_2\text{m}$ , which is well established as being eliminated by glomerular filtration, was positive and significant during uremia (Table 2).

$S\text{-}\alpha_1\text{m}$  did not differentiate between rejection and Cs nephrotoxicity, since the elevations paralleled the rises in  $s\text{-crea}$  that were observed in the two groups.

$S\text{-}\alpha_1\text{m}$  levels were not affected by infections, as is the case for  $s\text{-}\beta_2\text{m}$  and neopterin, both of which are considerably elevated during CMV infections [1, 2, 11, 12]. Similar observations have been made in connection with hepatobiliary disorders and malignancies, in which  $s\text{-}\alpha_1\text{m}$  levels have not been substantially elevated, but  $s\text{-}\beta_2\text{m}$  levels have [17].

During infections  $s\text{-crea}$  was significantly elevated, while  $s\text{-}\alpha_1\text{m}$  remained unchanged. A simultaneous increase in  $s\text{-}\alpha_1\text{m}$  during an infection may indicate rejection or Cs nephrotoxicity and should motivate other diagnostic approaches (e.g., biopsy), while an isolated  $s\text{-crea}$  elevation usually suggests an infection. During CMV infections a significant linear correlation between  $s\text{-crea}$  and  $s\text{-}\alpha_1\text{m}$  levels was found, but this was not the case during the other infections. This finding indicates that the rise in  $s\text{-crea}$  during CMV infections is due to a deterioration in renal function; however, in the case of other infections, another explanation for this increase must be sought.

It is well known that  $s\text{-crea}$  is not an ideal indicator of renal function and glomerular filtration and that the  $s\text{-crea}$  level may be normal even when glomerular filtration is reduced [13]. The  $s\text{-}\alpha_1\text{m}$  level might, therefore, be a better indicator of renal function and glomerular filtration than  $s\text{-crea}$ . It might also serve as a complement to  $s\text{-crea}$  in evaluating actual renal function in patients with slight renal deterioration.

*Acknowledgements.* This study was supported by grants from the Magn. Bergvalls Foundation and the Tore Nilssons Foundation

for Medical Research, as well as by The Swedish Medical Research Council (16X-05971).

## References

- Bäckman L, Ringdén O, Björkhem I, Lindbäck B (1986) Increased  $\beta_2$  microglobulin during rejection, cyclosporine induced nephrotoxicity and cytomegalovirus infection in renal transplant recipients. *Transplantation* 42: 368-371
- Bäckman L, Ringdén O, Björkhem I (1987) Monitoring of serum neopterin levels. Increased values during impaired renal function and cytomegalovirus infections. *Nephron* 46: 319-322
- Björkhem I, Blomstrand R, Öhman G (1977) Mass fragmentography of creatinine proposed as a reference method. *Clin Chem* 23: 2114-2121
- Canadian Multicentre Study Group (1983) A randomized trial of cyclosporine in cadaveric renal transplantation. *N Engl J Med* 309: 809-815
- Ekström B, Peterson PA, Berggård I (1975) A urinary and plasma  $\alpha_1$ -glycoprotein of low molecular weight: isolation and some properties. *Biochem Biophys Res Commun* 65: 1427-1433
- European Multicentre Trial Group (1983) Cyclosporin in cadaveric renal transplantation: one-year follow-up of a multicentre trial. *Lancet* II: 986-989
- Itoh Y, Enomoto H, Takagi K, Kawai T (1983) Clinical usefulness of serum  $\alpha_1$ -microglobulin as a sensitive indicator for renal insufficiency. *Nephron* 33: 69-70
- Kawai T, Takagi K (1982) Human alpha 1-microglobulin. Its physicochemical properties and clinical significance. *Asian Med J* 25: 251-270
- Klintmalm G, Ringdén O, Groth CG (1983) Clinical and laboratory signs in nephrotoxicity and rejection in cyclosporine treated renal allograft recipients. *Transplant Proc* 15: 2815-2820
- Kusano E, Suzuki M, Asano Y, Itoh Y, Takagi K, Kawai T (1985) Human  $\alpha_1$ -microglobulin and its relationship to renal function. *Nephron* 41: 320-324
- Margreiter R, Fuchs D, Hausen A, Hubert C, Reibnegger G, Spielberger M, Wachter H (1983) Neopterin as a new biochemical marker for diagnosis of allograft rejection. *Transplantation* 36: 650-653
- Norfolk DR, Barnard DL, Child JA (1981) Plasma  $\beta_2$ -microglobulin levels in bone marrow transplant patients with cytomegalovirus infections. *Lancet* I: 685-686
- Parving HH, Anderssen AR, Smidt UM (1985) Monitoring progression of diabetic nephropathy. *Ups J Med Sci* 90: 15-23
- Ringdén O, Öst L, Klintmalm G, Tillegård A, Fehrman I, Wilczek H, Groth CG (1983) Improved outcome in renal transplant recipients above 55 years of age treated with cyclosporine and low doses of steroids. *Transplant Proc* 15: 2507-2512
- Strober W, Waldmann TA (1974) The role of the kidney in the metabolism of plasma proteins. *Nephron* 13: 35-66
- Takagi K, Itoh Y, Enomoto H, Koyamaishi Y, Meada K, Kawai T (1980) A comparative study of serum  $\alpha_1$ -microglobulin levels in cancerous and other diseases. *Clin Chim Acta* 108: 277-283
- Takagi K, Kin K, Itoh Y, Enomoto H, Kawai T (1980) Human alpha 1-microglobulin levels in various body fluids. *J Clin Pathol* 33: 789-791
- Weber MH, Scholz P, Scheler F (1985) The role of alpha-1-microglobulin in the evaluation of tubular impairment and as a parameter superior to creatinine in the estimation of glomerular filtration rate. *Proc Eur Dial Transplant Assoc Eur Ren Assoc* 22: 1173-1177